Physician profile
Eric Kelley
NPI 1134102346
$1,790.61
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $395 · 2021: $449 · 2022: $235.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $586.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $288.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $207.71 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $207.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $139.30 | 2021-2022 | |
| Glaxosmithkline, LLC. | $128.05 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.57 | 2020-2022 | |
| Pfizer INC. | $102.03 | 2020-2021 | |
| Novo Nordisk INC | $16.15 | 2022 | |
| Hikma Pharmaceuticals USA | $12.58 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.